Who is affected by this change?

This affects Independence Blue Cross Hematology, Oncology providers on Commercial plans.

When does this change take effect?

This change is effective May 28, 2025.

Back to dashboard

CommercialCoverageLow impact

08.02.09b, Valoctocogene roxaparvovec-rvox (ROCTAVIAN™)

Independence Blue Cross·Hematology, Oncology·Pharmacy

Effective date

May 28, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A commercial insurance policy for Valoctocogene roxaparvovec-rvox (ROCTAVIAN™), a gene therapy medication, has been updated with a reissue effective date of May 28, 2025. This is a pharmacy policy update that will affect billing and coverage for this specialized hemophilia treatment.

Action Required

Action needed

By May 28, 2025: Billing team should review the updated policy details for Valoctocogene roxaparvovec-rvox (ROCTAVIAN™) gene therapy by accessing the full policy at the provided URL. Update any prior authorization requirements or coverage criteria in billing systems if changes are specified in the complete policy document.

Related policy hubs

Independence Blue Cross policies Hematology Oncology